Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating) CEO Jeffrey N. Simmons purchased 15,000 shares of the company’s stock in a transaction on Friday, March 10th. The shares were purchased at an average price of $9.60 per share, for a total transaction of $144,000.00. Following the purchase, the chief executive officer now owns 45,000 shares in the company, valued at approximately $432,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Elanco Animal Health Stock Down 2.9 %
Shares of ELAN opened at $9.29 on Tuesday. Elanco Animal Health Incorporated has a 52 week low of $9.27 and a 52 week high of $27.68. The company has a quick ratio of 1.02, a current ratio of 1.93 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $4.57 billion, a price-to-earnings ratio of -61.93, a PEG ratio of 6.54 and a beta of 0.95. The stock’s 50-day moving average price is $12.63 and its 200-day moving average price is $12.90.
Elanco Animal Health (NYSE:ELAN – Get Rating) last issued its quarterly earnings results on Tuesday, February 21st. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. The company had revenue of $988.00 million for the quarter, compared to the consensus estimate of $980.94 million. Elanco Animal Health had a positive return on equity of 7.57% and a negative net margin of 1.74%. Elanco Animal Health’s revenue for the quarter was down 11.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.21 earnings per share. On average, sell-side analysts predict that Elanco Animal Health Incorporated will post 0.77 EPS for the current year.
Institutional Investors Weigh In On Elanco Animal Health
Wall Street Analyst Weigh In
Several analysts have weighed in on the company. Piper Sandler dropped their price target on Elanco Animal Health from $15.00 to $12.00 in a research note on Thursday, March 2nd. Barclays dropped their price target on Elanco Animal Health from $18.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 22nd. Finally, Morgan Stanley dropped their price target on Elanco Animal Health from $20.00 to $19.00 and set an “equal weight” rating on the stock in a research note on Monday, January 30th. One analyst has rated the stock with a sell rating and six have assigned a hold rating to the stock. According to MarketBeat, Elanco Animal Health presently has an average rating of “Hold” and a consensus price target of $16.50.
About Elanco Animal Health
Elanco Animal Health, Inc innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine.
- Get a free copy of the StockNews.com research report on Elanco Animal Health (ELAN)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.